Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Study sponsor: Vir Biotechnology, Inc. · VIR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-03-25Actual
Enrollment · participants84Actual
Source updated2026-04-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.